16.07.2015 17:35:10
|
Actelion to discuss first half 2015 financial results
Actelion Pharmaceuticals Ltd / Actelion to discuss first half 2015 financial results . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Dear member of the investment community
Actelion Ltd will announce its half-year 2015 financial results on Tuesday, 21 July 2015, at 07:00hrs CEST / 06:00hrs BST / 1.00 a.m. EDT.
An investor conference call & webcast will be held at 14:00hrs, CEST to discuss the results.
To support your preparations, consensus estimates can be found under www.actelion.com/consensus-estimate
Date/Time:
21 July 2015 | 14:00hrs - 14:45hrs | Basel (CEST) |
13:00hrs - 13:45hrs | UK (BST) | |
8.00 a.m. - 8.45 a.m. | US (EDT) |
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before the conference is due to start.
Dial: | Europe: | +41 (0)44 583 18 01 | |||
UK: | +44 (0) 203 194 05 61 | ||||
US: | +1 855 228 38 74 |
Participant's mode:
Listen-Only with possibility to open individual lines during Q&A session.
Participants will be asked for their Name and Company.
Webcast Access:
Webcast participants should visit the Actelion website www.actelion.com 10-15 minutes before the conference is due to start.
Participant's mode: Listen-Only
Webcast Replay:
The archived Investor Webcast will be available for replay through www.actelion.com approximately 60 minutes after the call has ended.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Globenewswire
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Actelion Ltd.mehr Nachrichten
Keine Nachrichten verfügbar. |